TWI894261B - 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑 - Google Patents

作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑

Info

Publication number
TWI894261B
TWI894261B TW110114675A TW110114675A TWI894261B TW I894261 B TWI894261 B TW I894261B TW 110114675 A TW110114675 A TW 110114675A TW 110114675 A TW110114675 A TW 110114675A TW I894261 B TWI894261 B TW I894261B
Authority
TW
Taiwan
Prior art keywords
group
amino
anilino
thiazol
propionamide
Prior art date
Application number
TW110114675A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200552A (zh
Inventor
諾伯特 史奇米
爾里克 洛恩
丹尼斯 科奇霍夫
克利斯汀 彼得森
泰 勝 虞葉 恩古彥
麥瑞奇 葛瑞絲
尼可拉斯 渥貝可
爾芙 巴馬爾
班傑明 貝德
德特勒夫 施焦度
德克 科斯蒙德
瑞克 歐弗睿歌
科林納 林克
雷朋 卡翠恩 諾瓦客
厄瑞屈 羅森特雷特
Original Assignee
德商拜耳廠股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商拜耳廠股份有限公司 filed Critical 德商拜耳廠股份有限公司
Publication of TW202200552A publication Critical patent/TW202200552A/zh
Application granted granted Critical
Publication of TWI894261B publication Critical patent/TWI894261B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW110114675A 2020-04-24 2021-04-23 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑 TWI894261B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171280.9 2020-04-24
EP20171280 2020-04-24

Publications (2)

Publication Number Publication Date
TW202200552A TW202200552A (zh) 2022-01-01
TWI894261B true TWI894261B (zh) 2025-08-21

Family

ID=70464845

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110114675A TWI894261B (zh) 2020-04-24 2021-04-23 作為用於免疫活化之DGKζ抑制劑之經取代胺基噻唑

Country Status (32)

Country Link
US (3) US12673927B2 (cg-RX-API-DMAC7.html)
EP (2) EP4139286B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522251A (cg-RX-API-DMAC7.html)
KR (1) KR20230005247A (cg-RX-API-DMAC7.html)
CN (6) CN120093741A (cg-RX-API-DMAC7.html)
AR (1) AR121929A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021261524A1 (cg-RX-API-DMAC7.html)
CA (2) CA3180670A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002919A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014876A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220536A (cg-RX-API-DMAC7.html)
DK (1) DK4139286T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000223A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080829A (cg-RX-API-DMAC7.html)
ES (1) ES3029140T3 (cg-RX-API-DMAC7.html)
FI (1) FI4139286T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20257731B (cg-RX-API-DMAC7.html)
HR (1) HRP20250519T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071024T2 (cg-RX-API-DMAC7.html)
IL (1) IL297499A (cg-RX-API-DMAC7.html)
JO (1) JOP20220267A1 (cg-RX-API-DMAC7.html)
LT (1) LT4139286T (cg-RX-API-DMAC7.html)
MA (1) MA59379B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013388A (cg-RX-API-DMAC7.html)
PE (1) PE20230322A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552828A1 (cg-RX-API-DMAC7.html)
PL (1) PL4139286T3 (cg-RX-API-DMAC7.html)
PT (1) PT4139286T (cg-RX-API-DMAC7.html)
RS (1) RS66889B1 (cg-RX-API-DMAC7.html)
SI (1) SI4139286T1 (cg-RX-API-DMAC7.html)
TW (1) TWI894261B (cg-RX-API-DMAC7.html)
WO (2) WO2021214019A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CA3180670A1 (en) 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022114164A1 (ja) 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117510497A (zh) * 2022-07-29 2024-02-06 山东轩竹医药科技有限公司 DGKζ抑制剂
KR20250046309A (ko) * 2022-08-08 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN120957975A (zh) 2023-03-31 2025-11-14 拜耳公司 (r)-2-(n-[4-氨基-5-(4-甲氧基苯甲酰基)噻唑-2-基]-4-氟-苯胺基)丙酰胺的微晶形式及其制备方法
WO2024208198A1 (zh) * 2023-04-06 2024-10-10 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的噻唑类化合物
WO2024235203A1 (zh) * 2023-05-15 2024-11-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2025061020A1 (zh) * 2023-09-21 2025-03-27 楚浦创制(武汉)医药科技有限公司 苯并五元杂环衍生物及其制备方法与应用、药物组合物
WO2025067360A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 一种DGKzeta拮抗剂及其在医药上的应用
CN121586707A (zh) * 2023-10-17 2026-02-27 楚浦创制(武汉)医药科技有限公司 硫代羰基化合物及其应用
WO2025082460A1 (zh) * 2023-10-20 2025-04-24 上海先祥医药科技有限公司 二酰基甘油激酶抑制剂化合物及其应用
WO2025167814A1 (zh) * 2024-02-06 2025-08-14 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2026068294A1 (en) * 2024-09-24 2026-04-02 Bayer Aktiengesellschaft Improved nanoseeding process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006016A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2020006018A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
US20040132124A1 (en) 2002-03-22 2004-07-08 Prescott Stephen M. Neuroprotection by inhibition of diacyglycerol kinase epsilon activity
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
US20050137239A1 (en) 2003-12-17 2005-06-23 Hines Michelle D. Thiazole derivatives
NZ550114A (en) 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
JP2007533730A (ja) 2004-04-20 2007-11-22 アブ サイエンス 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
US20080004279A1 (en) 2004-04-23 2008-01-03 Alain Moussy Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases
EP1742633A2 (en) 2004-04-23 2007-01-17 AB Science Use of c-kit inhibitors for treating fibrosis
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
US20070249628A1 (en) 2004-05-18 2007-10-25 Alain Moussy Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007022415A2 (en) 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
KR100903974B1 (ko) 2007-09-27 2009-06-25 한국화학연구원 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 spc 수용체 활성으로 유발되는 염증관련 질환치료제
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
JP5322296B2 (ja) 2008-08-20 2013-10-23 日本曹達株式会社 テトラゾイルオキシム誘導体を含む植物病害防除剤の使用方法
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013033037A2 (en) 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
CN103058949A (zh) 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
CN103159695B (zh) 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
GB201307233D0 (en) 2013-04-22 2013-05-29 Vib Vzw Compounds and uses thereof
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Trpv4阻害活性を有する6員環誘導体
CN106109467B (zh) 2016-06-20 2020-04-17 中国药科大学 三类羧基取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途
WO2018089902A1 (en) 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
EP4013508A1 (en) * 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Nlrp3阻害剤
MX2022005376A (es) 2019-11-04 2022-05-19 Alector Llc Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
CA3180670A1 (en) 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006016A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2020006018A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators

Also Published As

Publication number Publication date
SI4139286T1 (sl) 2025-06-30
ECSP22080829A (es) 2022-11-30
MX2022013388A (es) 2022-11-30
CN120093740A (zh) 2025-06-06
US20230167078A1 (en) 2023-06-01
BR112022019057A2 (pt) 2022-11-08
WO2021214019A1 (en) 2021-10-28
EP4139287C0 (en) 2025-02-26
EP4139286A1 (en) 2023-03-01
CO2022014876A2 (es) 2023-03-17
TW202200552A (zh) 2022-01-01
PT4139286T (pt) 2025-05-21
PE20230322A1 (es) 2023-02-22
GEAP202416095A (en) 2024-08-26
PL4139286T3 (pl) 2025-08-11
US20230139936A1 (en) 2023-05-04
AU2021261524A1 (en) 2022-11-24
CN115697979B (zh) 2025-06-24
DOP2022000223A (es) 2022-11-15
AR121929A1 (es) 2022-07-27
GEP20257731B (en) 2025-02-10
JP2023522251A (ja) 2023-05-29
CN115697980B (zh) 2025-03-21
WO2021214020A1 (en) 2021-10-28
KR20230005247A (ko) 2023-01-09
CA3180819A1 (en) 2021-10-28
US20230167103A1 (en) 2023-06-01
LT4139286T (lt) 2025-05-12
JP2023522250A (ja) 2023-05-29
CR20220536A (es) 2023-01-17
US12673927B2 (en) 2026-07-07
HRP20250519T1 (hr) 2025-06-20
EP4139286B1 (en) 2025-02-26
JOP20220267A1 (ar) 2022-10-24
ES3029140T3 (en) 2025-06-23
CN115697979A (zh) 2023-02-03
IL297499A (en) 2022-12-01
CN120093739A (zh) 2025-06-06
RS66889B1 (sr) 2025-07-31
PH12022552828A1 (en) 2023-11-20
MA59379B1 (fr) 2025-04-30
CN115697980A (zh) 2023-02-03
FI4139286T3 (fi) 2025-05-07
EP4139287B1 (en) 2025-02-26
CN120093741A (zh) 2025-06-06
DK4139286T3 (da) 2025-05-05
CA3180670A1 (en) 2021-10-28
US11964953B2 (en) 2024-04-23
CN120093742A (zh) 2025-06-06
JP2025120943A (ja) 2025-08-18
EP4139287A1 (en) 2023-03-01
JP7663603B2 (ja) 2025-04-16
CL2022002919A1 (es) 2023-03-31
HUE071024T2 (hu) 2025-07-28

Similar Documents

Publication Publication Date Title
US11964953B2 (en) Substituted aminothiazoles as DGKzeta inhibitors for immune activation
CN115210238B (zh) 作为用于免疫激活的DGKα抑制剂的取代的氨基喹诺酮类
US20230062100A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CA2996318C (en) Heteroaryl compounds as irak inhibitors and uses thereof
JP2022533023A (ja) 統合的ストレス経路の調節剤としての置換シクロアルキル
KR20200096522A (ko) 통합된 스트레스 경로의 조절제
TW201827430A (zh) 4,5-環化1,2,4-三唑酮
EP3638670B1 (en) Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
EP3668880B1 (en) Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CN120813352A (zh) Dgk(二酰基甘油激酶)抑制剂的组合
EA048085B1 (ru) Замещенные аминотиазолы в качестве ингибиторов dgkzeta для иммунной активации
HK40081016B (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
HK40081016A (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
BR112022019057B1 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune, seus usos, composição e combinação farmacêuticas, e kit